



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
Bureau for Medical Services

Sherri A. Young, DO, MBA, FAAFP
Interim Cabinet Secretary

Cynthia E. Beane, MSW, LCSW
Commissioner

Pharmaceutical and Therapeutics Committee
August 23rd, 2023

Location: Webex only
Time: Executive Session 2:30 PM - 3:30 PM
Time: Open Session 3:30 PM – 5:00 PM
Charleston, WV 25301
(304) 558-1700

AGENDA

- I. Executive Session- 2:30PM-3:30PM
- II. Call to Order – Call in information for the 3:30 PM Open Session is 615-647-0981 meeting code **429 416 816#**
- III. Welcome and Introductions
- IV. Housekeeping Items/Updates
 - a. Approval of the April 26th, 2023, Minutes
 - b. PDL Compliance/Generic Percent Report Updates
- V. Public Comments (*Agenda classes only*) – Public comments for this meeting will only be accepted in writing. Comments need to be sent via email to Vicki Cunningham (Vicki.M.Cunningham@wv.gov) and Doug Sorvig (Richard.D.Sorvig@wv.gov) no later than August 9th, 2023. Comments will be forwarded to committee members prior to the meeting for their review and consideration.

Representatives of drug manufacturers being presented at P&T can register to be on hand to answer any questions put forth by P&T committee members. Registrants must provide a name, email address, name of drug and company they are representing, and provide a completed [disclosure form](#) to the email address above no later than August 9th, 2023.

- VI. New Business

a. New Drug Reviews

- i. Antibiotics, GI and Related Agents
 1. Vowst (fecal microbiota spores capsules)
- ii. Anticoagulants
 1. Pradaxa Oral pellets (dabigatran etexilate)
- iii. Antihemophilia Factor Agents
 1. Altuviiiio (antihemophilic factor)
- iv. Antimigraine Agents, Acute
 1. Zavzpret nasal spray (zavegepant)
- v. Antipsychotics, Atypical
 1. Abilify Asimtufi (aripiprazole)
 2. Uzedy (risperidone)
- vi. Growth Hormones and Achondroplasia Agents
 1. Sogroya (somapacitan-beco injection)
- vii. Hypoglycemics, Insulin and Related Agents
 1. Rezvoglar (insulin glargine-aglr)
- viii. Lipotropics, Statins
 1. Atorvaliq (atorvastatin)
- ix. PAH Agents – PDE5s
 1. Liqrev (sildenafil)
- x. Proton Pump Inhibitors
 1. Konvomep (omeprazole/sodium bicarbonate)
- xi. VMAT Inhibitors
 1. Austedo XR (deutetrabenazine)

b. Therapeutic Class Reviews

- i. Lipotropics, Other
 1. Leqvio (inclisiran)
- ii. Stimulants and Related Agents, Narcoleptic Agents
 1. sodium oxybate
 2. Sunosi (solriamfetol)
 3. Xyrem (sodium oxybate)
 4. Xywav (calcium, magnesium, potassium and sodium oxybate)
- iii. Miscellaneous Covered Agents
 1. Trikafta pak (elexacaftor/tezacaftor/ivacaftor & ivacaftor)

VII. Old Business

VIII. Other Business

IX. Next Meeting – **October 25th, 2023** In Person Meeting 2:00PM – 5:00PM

X. Adjournment